Koninklijke Philips (PHIA) Q1 2025 earnings summary

Executive summary

• Q1 2025 sales slightly exceeded outlook at EUR 4.1 billion, down 2% year-over-year, mainly due to double-digit declines in China, but supported by Personal Health growth and royalty phasing.

• Order intake grew 4% excluding China, with strong North America performance offsetting China weakness; order book improved in margin profile.

• Gross margin improved due to innovation and productivity, but adjusted EBITA/EBITDA margin declined 80 bps to 8.6%, supported by productivity and innovation.

• EUR 1 billion U.S. Respironics settlement was paid in Q1, funded by cash on hand, completing the U.S. litigation settlement.

• About 50% of sales now come from products launched in the last three years, highlighting AI-driven innovation.

Financial highlights

• Q1 2025 sales: EUR 4,097 million, down 2% year-over-year; adjusted EBITA: EUR 354 million (8.6% margin); free cash flow: -EUR 1,091 million, mainly due to the EUR 1 billion Respironics settlement.

• Net income rose to EUR 72 million, compared to a loss of EUR 998 million in Q1 2024, reflecting lower litigation and restructuring costs.

• Adjusted EBITDA margin was 13.9%, down from 14.7% year-over-year.

• Productivity initiatives delivered EUR 147 million in Q1 savings; on track for EUR 800 million in 2025.

• Adjusted diluted EPS from continuing operations was EUR 0.25, in line with last year.

Outlook and guidance

• 2025 comparable sales growth outlook remains at 1%-3%, with growth expected to be back-end loaded.

• Adjusted EBITA/EBITDA margin guidance lowered to 10.8%-11.3% (down 100 bps) due to tariffs, net of mitigations.

• Free cash flow for 2025 expected to be slightly positive, including the EUR 1 billion settlement outflow.

• Tariffs expected to have a EUR 250-300 million net annual impact after mitigations, with more pronounced effects in H2 2025.

• Outlook excludes potential impact of ongoing Respironics legal proceedings, including DOJ investigation.